Immunomedics inks deal with Syncor

Philips signs off on CEO’s replacement

Immunomedics has announced that Syncor International will distribute the radiopharmaceutical firm’s CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year with Bergen Brunswig (SCAN Special Report 6/98), which replaced a prior arrangement with Mallinckrodt.

Bergen Brunswig will provide nonradiolabeled CEA-Scan to Syncor, which will radiolabel the CEA-Scan with technetium at its 118 U.S. radiopharmacies, according to an Immunomedics spokesperson. Syncor, of Woodland Hills, CA, will then provide CEA-Scan to its customers in ready-to-use dosages. Syncor will also support Morris Plains, NJ-based Immunomedics with its own sales force.